文献速递妇科产科

早期宫颈癌FIGO-2018分期是否更好反映淋巴结转移风险

From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer; Does the revised staging reflect risk groups?
PubMed 文献 · Gynecol Oncol · 2021-09-06

该研究基于一项国家前瞻性队列中245例早期宫颈癌患者,将FIGO-2009分期重新分配为FIGO-2018分期,评估新分期对淋巴结转移风险的预测能力。结果显示54.7%的患者发生分期迁移,FIGO-2018≥IB2、浸润深度>2/3及淋巴血管间隙浸润与淋巴结转移显著相关,而降期至IA期者均无淋巴结转移。

要点

  • FIGO-2018分期导致54.7%的早期宫颈癌患者发生分期迁移。
  • FIGO-2018≥IB2、浸润深度>2/3及LVSI是淋巴结转移的独立危险因素。
  • 降期至FIGO-2018 IA期的14例患者均无淋巴结转移。

核心结论

  • FIGO-2018分期修订导致大部分早期宫颈癌患者发生分期迁移。
  • 降期至FIGO-2018 IA期的患者未出现淋巴结转移。
  • 关注浸润深度而非水平维度似乎能正确反映淋巴结转移风险。

研究设计与样本

  • 基于一项国家前瞻性队列研究,纳入245例早期宫颈癌女性。
  • 利用前哨淋巴结定位数据,将FIGO-2009分期重新分配为FIGO-2018分期。
  • 采用单因素和多因素二元回归模型分析分期、肿瘤特征与淋巴结转移的关联。

主要发现

  • 分期迁移发生率为54.7%(134/245,95%CI 48.2-61.0),其中因肿瘤大小或浸润深度占71.6%(96/134),因淋巴结转移占28.4%(38/134)。
  • 术前影像学使7.3%(18/245)患者分期升高,其中7例最终病理证实淋巴结转移。
  • 49.8%(122/245,95%CI 43.4-56.2%)患者分期升高,4.9%(12/245,95%CI 2.6-8.4)降期至FIGO-2018 IA期。
  • FIGO-2018 IA期肿瘤特征者肿瘤大小为3.0-19.0 mm,14例中无一例淋巴结转移。
  • 多因素分析中,与淋巴结转移显著相关的因素包括FIGO-2018≥IB2(RR 5.01,95%CI 2.30-10.93,p<0.001)、浸润深度>2/3(RR 1.88,95%CI 1.05-3.35,p=0.033)及淋巴血管间隙浸润(RR 5.56,95%CI 2.92-10.62,p<0.001)。

关键数值与推荐

  • FIGO-2018≥IB2:淋巴结转移风险比RR 5.01(95%CI 2.30-10.93,p<0.001)。
  • 浸润深度>2/3:淋巴结转移风险比RR 1.88(95%CI 1.05-3.35,p=0.033)。
  • 淋巴血管间隙浸润:淋巴结转移风险比RR 5.56(95%CI 2.92-10.62,p<0.001)。

临床怎么用

  • 临床应采用FIGO-2018分期评估早期宫颈癌淋巴结转移风险。
  • 对FIGO-2018≥IB2、浸润深度>2/3或LVSI阳性者应警惕淋巴结转移。
  • FIGO-2018 IA期患者淋巴结转移风险低,可考虑减少不必要的淋巴结评估。

局限性

  • 研究基于前瞻性队列的二次分析,可能存在选择偏倚。
  • 样本量有限(245例),部分亚组病例数较少(如IA期14例)。
  • 未报告前哨淋巴结定位的具体方法和随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aimed to evaluate if the revised staging according to FIGO-2018 in early-stage cervical cancer correctly predicts the risk for nodal metastases. METHODS: We reallocated 245 women with early-stage cervical cancer from FIGO-2009 to FIGO-2018 stages using data from a national, prospective cohort study on sentinel lymph node (SLN) mapping. We used univariate and multivariate binary regression models to investigate the association between FIGO-2018 stages, tumor characteristics, and nodal metastases. RESULTS: Stage migration occurred in 54.7% (134/245) (95% CI 48.2-61.0), due to tumor size or depth of invasion (71.6%, 96/134) and nodal metastases (28.4%, 38/134). Imaging preoperatively upstaged 7.3% (18/245); seven had nodal metastatic disease on final pathology. Upstaging occurred in 49.8% (122/245) (95% CI 43.4-56.2%) and downstaging to FIGO-2018 IA stages in 4.9% (12/245) (95% CI 2.6-8.4). The tumor size ranged from 3.0-19.0 mm in women with FIGO-2018 IA tumor characteristics, and none of the 14 women had nodal metastases. In multivariate analysis, risk factors significantly associated with nodal metastases were FIGO-2018 ≥ IB2 (RR 5.01, 95% CI 2.30-10.93, p < 0.001), proportionate depth of invasion >2/3 (RR 1.88, 95% CI 1.05-3.35, p = 0.033), and lymphovascular space invasion (RR 5.56, 95% CI 2.92-10.62, p < 0.001). CONCLUSIONS: The FIGO-2018 revised staging system causes stage migration for a large proportion of women with early-stage cervical cancer. Women who were downstaged to FIGO-2018 IA stages did not have nodal metastatic disease. The attention on depth of invasion rather than horizontal dimension seems to correctly reflect the risk of nodal metastases.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Sponholtz SE, Mogensen O, Hildebrandt MG, et al. From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer; Does the revised staging reflect risk groups? Gynecol Oncol. 2021. PMID: 34503847. doi:10.1016/j.ygyno.2021.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。